脂蛋白(a)：急性ST段抬高型心肌梗死的潜在新靶点
Lipoprotein (a): A Potential New Target for Acute ST-Segment Elevation Myocardial Infarction
DOI: 10.12677/ACM.2023.13122657, PDF,   
作者: 郝贝贝：西安医学院临床医学系，陕西 西安；陕西省人民医院心血管内三科，陕西 西安；崔明亮, 杨禹娟, 刘新宏：陕西省人民医院心血管内三科，陕西 西安
关键词: 脂蛋白(a)；ST段抬高型心肌梗死；Lipoprotein (a)； ST-Segment Elevation Myocardial Infarction
摘要: 动脉粥样硬化性心血管疾病(Atherosclerotic Cardiovascular Disease, ASCVD)居全球心血管疾病(Cardiovascular Disease, CVD)首位，并成为当今全球人类死亡的首要原因，ST段抬高型心肌梗死(ST-segment Elevation Myocardial Infarction, STEMI)作为其最急性的临床表现，严重威胁人类的健康和生存质量。而血脂异常加速动脉粥样硬化(Atherosclerosis, AS)的形成，是ASCVD发生的核心机制。其中低密度脂蛋白胆固醇(Low-density Lipoproteins Cholesterol, LDL-C)作为重要的血脂指标，其水平控制在当今指南理想范围之内仍存在心血管事件(Cardiovascular Events, CVE)残余风险，这强调寻找新型潜在脂质生物标志物作为ASCVD发展风险预测因子的必要性。脂蛋白(a) [Lipoprotein a, Lp (a)]已被证明在AS中起因果作用，同时也是CVD患者中最佳降脂治疗后残余风险的主要贡献者。本综述旨在讲述Lp (a)致STEMI的发生机制，两者之间的相关性及治疗。
Abstract: Atherosclerotic Cardiovascular Disease ranks first in the global cardiovascular disease. ST-segment elevation myocardial infarction as its most acute clinical manifestation is a serious threat to human health and quality of life. And dyslipidemia accelerates the formation of atherosclerosis, which is the core mechanism of the occurrence of atherosclerotic cardiovascular disease. Among them, LDL cholesterol as an important lipid index, still has residual risk of cardiovascular events within the ideal range of the current guidelines, which emphasizes the need to find novel potential lipid bi-omarkers as predictors of risk for the development of atherosclerotic cardiovascular disease. Lipo-protein (a) has been shown to play a causal role in atherosclerosis and is also a major contributor to residual risk after optimal lipid-lowering therapy in patients with cardiovascular disease world-wide. The purpose of this review is to describe the pathogenesis, correlation and treatment of ST-elevation myocardial infarction induced by lipoprotein (a).
文章引用：郝贝贝, 崔明亮, 杨禹娟, 刘新宏. 脂蛋白(a)：急性ST段抬高型心肌梗死的潜在新靶点[J]. 临床医学进展, 2023, 13(12): 18890-18897. https://doi.org/10.12677/ACM.2023.13122657

参考文献

[1] Rich, M.W. (2006) Epidemiology, Clinical Features, and Prognosis of Acute Myocardial Infarction in the Elderly. The American Journal of Geriatric Cardiology, 15, 7-13. [Google Scholar] [CrossRef] [PubMed]
[2] van Peet, P.G., Drewes, Y.M., de Craen, A.J., Gussekloo, J. and de Ruijter, W. (2013) NT-proBNP Best Predictor of Car-diovascular Events and Cardiovascular Mortality in Secondary Prevention in Very Old Age: The Leiden 85-Plus Study. PLOS ONE, 8, e81400. [Google Scholar] [CrossRef] [PubMed]
[3] Zhang, M., Liu, H.H., Jin, J.L., et al. (2020) Lipoprotein (a) and Cardiovascular Death in Oldest-Old (≥ 80 Years) Patients with Acute Myocardial Infarction: A Prospective Cohort Study. Atherosclerosis, 312, 54-59. [Google Scholar] [CrossRef] [PubMed]
[4] Tsimikas, S., Fazio, S., Ferdinand, K.C., et al. (2018) NHLBI Working Group Recommendations to Reduce Lipoprotein (a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College of Cardiology, 71, 177-192. [Google Scholar] [CrossRef] [PubMed]
[5] Berg, K. (1963) A New Serum Type System in Man—The Lp Sys-tem. Acta Pathologica Microbiologica Scandinavica, 59, 369-382. [Google Scholar] [CrossRef] [PubMed]
[6] Catapano, A.L., Graham, I., De Backer, G., et al. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidae-mias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the Special Contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Athero-sclerosis, 253, 281-344.
[7] Gencer, B., Kronenberg, F., Stroes, E.S. and Mach, F. (2017) Lipoprotein (a): The Reve-nant. European Heart Journal, 38, 1553-1560. [Google Scholar] [CrossRef] [PubMed]
[8] Schmidt, K., Noureen, A., Kronenberg, F. and Utermann, G. (2016) Structure, Function, and Genetics of Lipoprotein (a). Journal of Lipid Re-search, 57, 1339-1359. [Google Scholar] [CrossRef] 
[9] Nordestgaard, B.G. and Langsted, A. (2016) Lipoprotein (a) as a Cause of Cardiovascular Disease: Insights from Epidemiology, Genetics, and Biology. Journal of Li-pid Research, 57, 1953-1975. [Google Scholar] [CrossRef] 
[10] Cesaro, A., Schiavo, A., Moscarella, E., et al. (2021) Lipoprotein (a): A Genetic Marker for Cardiovascular Disease and Target for Emerging Therapies. Journal of Cardiovascular Medicine, 22, 151-161. [Google Scholar] [CrossRef] 
[11] Vavuranakis, M.A., Jones, S.R., Ziogos, E., et al. (2022) The Trajectory of Lipoprotein (a) during the Peri- and Early Postinfarction Period and the Impact of Proprotein Convert-ase Subtilisin/Kexin Type 9 Inhibition. The American Journal of Cardiology, 171, 1-6. [Google Scholar] [CrossRef] [PubMed]
[12] Mitsuda, T., Uemura, Y., Ishii, H., et al. (2016) Lipoprotein (a) Levels Predict Adverse Vascular Events after Acute Myocardial Infarction. Heart and Vessels, 31, 1923-1929. [Google Scholar] [CrossRef] [PubMed]
[13] Rashid, S., Khurshid, R., Amir, U.F., et al. (2017) A Novel Link between Adipokines and Lipoprotein (A) to Contemplate Their Diagnostic Role in Patients with Stemi and Nstemi. Journal of Ayub Medical College Abbottabad, 29, 112-117.
[14] Galasso, G., De Angelis, E., Silverio, A., et al. (2021) Predictors of Recurrent Ischemic Events in Patients with ST- Segment Elevation Myocardial Infarction. The American Journal of Cardiology, 159, 44-51. [Google Scholar] [CrossRef] [PubMed]
[15] Kronenberg, F., Mora, S., Stroes, E., et al. (2022) Lipoprotein (a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal, 43, 3925-3946. [Google Scholar] [CrossRef] [PubMed]
[16] Ruscica, M., Sirtori, C.R., Corsini, A., et al. (2021) Lipoprotein (a): Knowns, Unknowns and Uncertainties. Pharmacological Research, 173, Article ID: 105812. [Google Scholar] [CrossRef] [PubMed]
[17] Bdeir, K., Cane, W., Canziani, G., et al. (1999) Defensin Promotes the Binding of Lipoprotein (a) to Vascular Matrix. Blood, 94, 2007-2019.
[18] Kreuzer, J., Lloyd, M.B., Bok, D., et al. (1994) Lipoprotein (a) Displays Increased Accumulation Compared with Low- Density Lipoprotein in the Murine Arteri-al Wall. Chemistry and Physics of Lipids, 67-68, 175-190. [Google Scholar] [CrossRef] [PubMed]
[19] Oikonomou, E., Souvaliotis, N., Lampsas, S., et al. (2022) Endothelial Dysfunction in Acute and Long Standing COVID-19: A Prospective Cohort Study. Vascular Pharmacology, 144, Article ID: 106975. [Google Scholar] [CrossRef] [PubMed]
[20] Sotiriou, S.N., Orlova, V.V., Al-Fakhri, N., et al. (2006) Lipopro-tein (a) in Atherosclerotic Plaques Recruits Inflammatory Cells through Interaction with Mac-1 Integrin. The FASEB Journal, 20, 559-561. [Google Scholar] [CrossRef] [PubMed]
[21] Klezovitch, O., Edelstein, C. and Scanu, A.M. (2001) Stimulation of In-terleukin-8 Production in Human THP-1 Macrophages by Apolipoprotein (a). Evidence for a Critical Involvement of Elements in Its C-Terminal Domain. Journal of Biological Chemistry, 276, 46864-46869. [Google Scholar] [CrossRef] 
[22] Labudovic, D., Kostovska, I., Tosheska, T.K., et al. (2019) Lipopro-tein (a)—Link between Atherogenesis and Thrombosis. Prague Medical Report, 120, 39-51. [Google Scholar] [CrossRef] [PubMed]
[23] Grainger, D.J., Kemp, P.R., Liu, A.C., Lawn, R.M. and Metcalfe, J.C. (1994) Activation of Transforming Growth Factor-β Is Inhibited in Transgenic Apolipoprotein(a) Mice. Nature, 370, 460-462. [Google Scholar] [CrossRef] [PubMed]
[24] Badimon, L., Padro, T., Arderiu, G., et al. (2022) Extracellular Vesicles in Atherothrombosis: From Biomarkers and Precision Medicine to Therapeutic Targets. Immunological Reviews, 312, 6-19. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, C., Liu, C., Shi, J., et al. (2023) Nicotine Exacerbates Endothelial Dysfunction and Drives Atherosclerosis via Extracellular Vesicle-miRNA. Cardiovascular Research, 119, 729-742. [Google Scholar] [CrossRef] [PubMed]
[26] Klezovitch, O., Edelstein, C., Zhu, L.Y. and Scanu, A.M. (1998) Apolipoprotein (a) Binds via Its C-Terminal Domain to the Protein Core of the Proteoglycan Decorin. Implications for the Retention of Lipoprotein (a) in Atherosclerotic Lesions. Journal of Biological Chemistry, 273, 23856-23865. [Google Scholar] [CrossRef] [PubMed]
[27] Ganne, F., Vasse, M., Beaudeux, J.L., et al. (1999) Increased Ex-pression of u-PA and u-PAR on Monocytes by LDL and Lp(a) Lipoproteins—Consequences for Plasmin Generation and Monocyte Adhesion. Thrombosis and Haemostasis, 81, 594-600. [Google Scholar] [CrossRef] 
[28] Sankhesara, D.M., Lan, N., Gilfillan, P., et al. (2023) Lipoprotein (a) Is Associated with Thrombus Burden in Culprit Arteries of Younger Patients with ST-Segment Elevation Myocardial In-farction. Cardiology, 148, 98-102. [Google Scholar] [CrossRef] [PubMed]
[29] Neeland, I.J., Patel, R.S., Eshtehardi, P., et al. (2012) Coronary Angio-graphic Scoring Systems: An Evaluation of Their Equivalence and Validity. American Heart Journal, 164, 547-552. [Google Scholar] [CrossRef] [PubMed]
[30] Xue, Y., Jian, S., Zhou, W., et al. (2021) Associations of Lipopro-tein(a) with Coronary Atherosclerotic Burden and All-Cause Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 8, Article 638679. [Google Scholar] [CrossRef] [PubMed]
[31] Ferretti, G., Bacchetti, T., Johnston, T.P., et al. (2018) Lipoprotein (a): A Missing Culprit in the Management of Athero-Thrombosis? Journal of Cellular Physiology, 233, 2966-2981. [Google Scholar] [CrossRef] [PubMed]
[32] Caplice, N.M., Panetta, C., Peterson, T.E., et al. (2001) Lipoprotein (a) Binds and Inactivates Tissue Factor Pathway Inhibitor: A Novel Link between Lipoproteins and Thrombosis. Blood, 98, 2980-2987. [Google Scholar] [CrossRef] 
[33] Scanu, A.M. (2003) Lipoprotein (a) and the Atherothrombotic Process: Mechanistic Insights and Clinical Implications. Current Atherosclerosis Reports, 5, 106-113. [Google Scholar] [CrossRef] [PubMed]
[34] Boffa, M.B. and Koschinsky, M.L. (2016) Lipoprotein (a): Truly a Direct Prothrombotic Factor in Cardiovascular Disease? Journal of Lipid Research, 57, 745-757. [Google Scholar] [CrossRef] 
[35] Ezratty, A., Simon, D.I. and Loscalzo, J. (1993) Lipoprotein (a) Binds to Human Platelets and Attenuates Plasminogen Binding and Activation. Biochemistry, 32, 4628-4633. [Google Scholar] [CrossRef] [PubMed]
[36] van der Valk, F.M., Bekkering, S., Kroon, J., et al. (2016) Oxidized Phospholipids on Lipoprotein (a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 134, 611-624. [Google Scholar] [CrossRef] 
[37] Lee, S., Birukov, K.G., Romanoski, C.E., et al. (2012) Role of Phospholipid Oxidation Products in Atherosclerosis. Circulation Research, 111, 778-799. [Google Scholar] [CrossRef] 
[38] Wang, Y., Zhao, X., Zhou, P., et al. (2021) Impact of Postprocedural High-Sensitivity C-Reactive Protein on Lipoprotein (a)-Associated Cardiovascular Risk with ST-Segment Elevation Myocardial Infarction with Percutaneous Coronary Intervention. The American Journal of Cardiology, 150, 8-14. [Google Scholar] [CrossRef] [PubMed]
[39] Ray, K.K., Stoekenbroek, R.M., Kallend, D., et al. (2018) Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Circulation, 138, 1304-1316. [Google Scholar] [CrossRef] 
[40] Dyrbus, K., Gasior, M., Penson, P., Ray, K.K. and Banach, M. (2020) Inclisiran-New Hope in the Management of Lipid Disorders? Journal of Clinical Lipidology, 14, 16-27. [Google Scholar] [CrossRef] [PubMed]
[41] Raal, F.J., Giugliano, R.P., Sabatine, M.S., et al. (2016) PCSK9 Inhibition-Mediated Reduction in Lp (a) with Evolocumab: An Analysis of 10 Clinical Trials and the LDL Re-ceptor’s Role. Journal of Lipid Research, 57, 1086-1096. [Google Scholar] [CrossRef] 
[42] Enas, E.A., Varkey, B., Dharmarajan, T.S., Pare, G. and Bahl, V.K. (2019) Lipoprotein (a): An Independent, Genetic, and Causal Factor for Cardiovascular Disease and Acute Myocardial Infarction. Indian Heart Journal, 71, 99-112. [Google Scholar] [CrossRef] [PubMed]
[43] Tsimikas, S., Viney, N.J., Hughes, S.G., et al. (2015) Antisense Therapy Targeting Apolipoprotein (a): A Randomised, Double-Blind, Placebo-Controlled Phase 1 Study. The Lancet, 386, 1472-1483. [Google Scholar] [CrossRef] 
[44] Xue, Y., Shen, J., Hong, W., et al. (2021) Risk Stratification of ST-Segment Elevation Myocardial Infarction (STEMI) Patients Using Machine Learning Based on Lipid Profiles. Li-pids in Health and Disease, 20, Article No. 48. [Google Scholar] [CrossRef] [PubMed]

为你推荐